Jeremy G Stewart1, Kate L Harkness. 1. Department of Psychology, Queen's University, 62 Arch St, Kingston, Ontario, Canada. 2js4@queensu.ca
Abstract
BACKGROUND:Antidepressant medications, Cognitive-Behavioral Therapy (CBT) and Interpersonal Psychotherapy (IPT) are equally efficacious in the acute treatment of Major Depressive Disorder (MDD). Nevertheless, remission rates remain unacceptably low. Examining the differential time course of remission of specific symptom clusters across treatments may provide a basis for assigning patients to treatments that have the highest chance of being effective. METHODS: This study re-analyzed data from the NIMH Treatment of Depression Collaborative Research Project (TDCRP), which included 250 adult outpatients with MDD randomized to 16 weeks ofCBT, IPT, imipramine+clinical management (IMI-CM), or pill placebo (PLA-CM). We derived four symptom factors from the 23-item Hamilton Depression Rating Scale, and three symptom factors from the Beck Depression Inventory. Within-subject hierarchical regression models were specified to examine the linear and quadratic patterns of symptom remission over five assessment points. RESULTS: IMI-CM produced a more rapid rate of remission than CBT or IPT for both the somatic/vegetative and cognitive-affective symptoms of MDD. There were no statistically significant differences in the rates of improvement of any of the symptom factors between the IMI-CM and PLA-CM groups. LIMITATIONS: Some core symptoms of depression were excluded due to low factor loadings. Past research has argued that the CBT arm in the TDCRP may have been weak. CONCLUSIONS: We failed to find evidence that treatments act preferentially on specific symptom clusters. Therefore, the symptoms of MDD may be inter-dependent when it comes to their courses of remission in treatment.
RCT Entities:
BACKGROUND: Antidepressant medications, Cognitive-Behavioral Therapy (CBT) and Interpersonal Psychotherapy (IPT) are equally efficacious in the acute treatment of Major Depressive Disorder (MDD). Nevertheless, remission rates remain unacceptably low. Examining the differential time course of remission of specific symptom clusters across treatments may provide a basis for assigning patients to treatments that have the highest chance of being effective. METHODS: This study re-analyzed data from the NIMH Treatment of Depression Collaborative Research Project (TDCRP), which included 250 adult outpatients with MDD randomized to 16 weeks of CBT, IPT, imipramine+clinical management (IMI-CM), or pill placebo (PLA-CM). We derived four symptom factors from the 23-item Hamilton Depression Rating Scale, and three symptom factors from the Beck Depression Inventory. Within-subject hierarchical regression models were specified to examine the linear and quadratic patterns of symptom remission over five assessment points. RESULTS: IMI-CM produced a more rapid rate of remission than CBT or IPT for both the somatic/vegetative and cognitive-affective symptoms of MDD. There were no statistically significant differences in the rates of improvement of any of the symptom factors between the IMI-CM and PLA-CM groups. LIMITATIONS: Some core symptoms of depression were excluded due to low factor loadings. Past research has argued that the CBT arm in the TDCRP may have been weak. CONCLUSIONS: We failed to find evidence that treatments act preferentially on specific symptom clusters. Therefore, the symptoms of MDD may be inter-dependent when it comes to their courses of remission in treatment.
Authors: Boadie W Dunlop; Steven P Cole; Charles B Nemeroff; Helen S Mayberg; W Edward Craighead Journal: J Affect Disord Date: 2017-12-27 Impact factor: 4.839
Authors: Robert M Carney; Kenneth E Freedland; Brian C Steinmeyer; Eugene H Rubin; Michael W Rich Journal: Psychosom Med Date: 2018-05 Impact factor: 4.312
Authors: Lynn Boschloo; Ella Bekhuis; Erica S Weitz; Mirjam Reijnders; Robert J DeRubeis; Sona Dimidjian; David L Dunner; Boadie W Dunlop; Ulrich Hegerl; Steven D Hollon; Robin B Jarrett; Sidney H Kennedy; Jeanne Miranda; David C Mohr; Anne D Simons; Gordon Parker; Frank Petrak; Stephan Herpertz; Lena C Quilty; A John Rush; Zindel V Segal; Jeffrey R Vittengl; Robert A Schoevers; Pim Cuijpers Journal: World Psychiatry Date: 2019-06 Impact factor: 49.548
Authors: Annelieke M Roest; Robert M Carney; Kenneth E Freedland; Elisabeth J Martens; Johan Denollet; Peter de Jonge Journal: J Affect Disord Date: 2013-03-11 Impact factor: 4.839
Authors: Michael F Grunebaum; John G Keilp; Steven P Ellis; Katherin Sudol; Neal Bauer; Ainsley K Burke; Maria A Oquendo; J John Mann Journal: J Clin Psychiatry Date: 2013-09 Impact factor: 4.384
Authors: Jay C Fournier; Robert J DeRubeis; Steven D Hollon; Robert Gallop; Richard C Shelton; Jay D Amsterdam Journal: Behav Res Ther Date: 2013-04-12
Authors: Sudha Prathikanti; Renee Rivera; Ashly Cochran; Jose Gabriel Tungol; Nima Fayazmanesh; Eva Weinmann Journal: PLoS One Date: 2017-03-16 Impact factor: 3.240